On Wednesday, April 2, I am participating in a roundtable webinar with the Cancer Support Community on Utilization Management. We will discuss the recent prior authorization and formulary changes being used by insurers to delay or deny patients’ access to Libtayo or Revlimid. As I have recently experienced this denial of Revlimid, that will be my role on the panel. If you are interested, here is the link to sign up; https://events.zoom.us/ev/Aj20IEYrxUTUTJvmuZRZYoK0coIymO172n9rJbxSXr4y7Edaj4J9~AuKsJhJs6t_WcTqHERh5jfXlOUo0_ccTSEwY2RzY62ezzKufnBEdtv7wYQ?eType=EmailBlastContent&eId=117faff7-9e6b-4c66-a0ae-c1f626f9279e